<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82450">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02100748</url>
  </required_header>
  <id_info>
    <org_study_id>CP130-2001</org_study_id>
    <nct_id>NCT02100748</nct_id>
  </id_info>
  <brief_title>A Study of TRV130 for the Treatment of Pain After Bunionectomy</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-blind, Multiple-dose, Adaptive, Placebo- and Active-controlled Study of TRV130 for the Treatment of Acute Postoperative Pain After Bunionectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trevena Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trevena Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the analgesic efficacy of IV TRV130 compared with
      placebo in patients with acute postoperative pain after bunionectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to evaluate the analgesic efficacy of IV TRV130 compared with
      placebo in patients with acute postoperative pain after bunionectomy.  Additional objectives
      are to evaluate the efficacy and safety of TRV130 compared to morphine.  Pharmacokinetics of
      TRV130 and morphine will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Reduction of Pain Intensity following Bunionectomy</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pain intensity will be evaluated by an 11-point numeric rating scale administered intermittently over 48 hours</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>TRV130 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TRV130 1 mg IV Q4H x 48 h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRV130 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TRV130 2 mg IV Q4H x 48 h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRV130 3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TRV130 3 mg IV Q4H x 48 h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRV130 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TRV130 4 mg IV Q4H x 48 h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Morphine 4 mg IV Q4H x 48 h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (D5W) IV Q4H x 48 h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRV130</intervention_name>
    <description>TRV130 1 - 4 mg will be administered every 4 hours</description>
    <arm_group_label>TRV130 1 mg</arm_group_label>
    <arm_group_label>TRV130 2 mg</arm_group_label>
    <arm_group_label>TRV130 3 mg</arm_group_label>
    <arm_group_label>TRV130 4 mg</arm_group_label>
    <other_name>TRV130</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Morphine 4 mg will be administered every 4 hours</description>
    <arm_group_label>Morphine</arm_group_label>
    <other_name>Morphine sulphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered every 4 hours</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Dextrose 5% in water</other_name>
    <other_name>D5W</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has undergone primary, unilateral, first metatarsal bunionectomy (osteotomy and
             internal fixation) with no additional collateral procedures.

          -  Experiences a pain intensity rating of â‰¥ 4 on an 11 point NRS

          -  Able to provide written informed consent before any study procedure.

        Exclusion Criteria:

          -  ASA Physical Status Classification System classification of P3 or worse

          -  Has surgical or post-surgical complications.

          -  Has clinically significant medical conditions or history of such conditions that may
             interfere with the interpretation of efficacy, safety, or tolerability data obtained
             in the trial, or may interfere with the absorption, distribution, metabolism, or
             excretion of drugs.

          -  Has previously participated in another TRV130 clinical study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franck Skobieranda, MD</last_name>
    <role>Study Director</role>
    <affiliation>Trevena Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruth A Subach, PharmD</last_name>
    <phone>610-354-8840</phone>
    <phone_ext>250</phone_ext>
    <email>rsubach@trevenainc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Premier Research</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Recruitment Department</last_name>
      <phone>866-788-3921</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Premier Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Recruitment Department</last_name>
      <phone>800-320-1630</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICON Development Solutions</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Recruitment Department</last_name>
      <phone>210-225-5437</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 1, 2014</lastchanged_date>
  <firstreceived_date>March 23, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>moderate to severe acute pain</keyword>
  <keyword>bunionectomy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
